UA73281C2 - Antitumor pharmaceutical composition based on carboplatin - Google Patents

Antitumor pharmaceutical composition based on carboplatin Download PDF

Info

Publication number: UA73281C2
Authority: UA; Ukraine
Prior art keywords: carboplatin; cyclobutanedicarboxylic acid; pharmaceutical composition; concentration; aqueous solution
Prior art date: 1998-08-14

Application number

UA2001021022A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Pliva Lachema As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-14

Filing date

1999-10-08

Publication date

2005-07-15

1999-10-08 Application filed by Pliva Lachema As filed Critical Pliva Lachema As

2005-07-15 Publication of UA73281C2 publication Critical patent/UA73281C2/uk

Links

229960004562 carboplatin Drugs 0.000 title claims abstract description 92
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
230000000259 anti-tumor effect Effects 0.000 title claims abstract description 5
190000008236 carboplatin Chemical compound 0.000 title 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims abstract description 90
CCQPAEQGAVNNIA-UHFFFAOYSA-N cyclobutane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-N 0.000 claims abstract description 31
238000002360 preparation method Methods 0.000 claims abstract description 20
239000007864 aqueous solution Substances 0.000 claims abstract description 19
150000003839 salts Chemical class 0.000 claims abstract description 8
238000012876 topography Methods 0.000 claims 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
239000000243 solution Substances 0.000 description 14
238000003860 storage Methods 0.000 description 12
238000000354 decomposition reaction Methods 0.000 description 10
239000002253 acid Substances 0.000 description 7
239000013543 active substance Substances 0.000 description 7
239000007788 liquid Substances 0.000 description 7
230000009467 reduction Effects 0.000 description 6
238000010998 test method Methods 0.000 description 5
239000000872 buffer Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
230000007062 hydrolysis Effects 0.000 description 4
238000006460 hydrolysis reaction Methods 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
230000000269 nucleophilic effect Effects 0.000 description 4
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
230000000052 comparative effect Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000003446 ligand Substances 0.000 description 3
230000007774 longterm Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
229910052697 platinum Inorganic materials 0.000 description 3
230000006641 stabilisation Effects 0.000 description 3
238000011105 stabilization Methods 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
-1 carboplatin monohydrate Chemical class 0.000 description 2
150000007942 carboxylates Chemical group 0.000 description 2
150000004683 dihydrates Chemical class 0.000 description 2
238000007323 disproportionation reaction Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000003301 hydrolyzing effect Effects 0.000 description 2
238000012417 linear regression Methods 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000000203 mixture Substances 0.000 description 2
150000004682 monohydrates Chemical class 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
208000031404 Chromosome Aberrations Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
231100000005 chromosome aberration Toxicity 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000003912 environmental pollution Methods 0.000 description 1
159000000011 group IA salts Chemical class 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000009776 industrial production Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
238000000034 method Methods 0.000 description 1
239000012038 nucleophile Substances 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003057 platinum Chemical class 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/0091—Complexes with metal-heteroatom-bonds

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

UA2001021022A 1998-08-14 1999-10-08 Antitumor pharmaceutical composition based on carboplatin UA73281C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CZ19982588A CZ292170B6 (cs)	1998-08-14	1998-08-14	Farmaceutická kompozice s protinádorovým účinkem na bázi carboplatiny
PCT/CZ1999/000028 WO2000009097A2 (fr)	1998-08-14	1999-08-10	Composition pharmaceutique a activite anticancereuse a base de carboplatine

Publications (1)

Publication Number	Publication Date
UA73281C2 true UA73281C2 (en)	2005-07-15

Family

ID=5465233

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2001021022A UA73281C2 (en)	1998-08-14	1999-10-08	Antitumor pharmaceutical composition based on carboplatin

Country Status (17)

Country	Link
US (1)	US6589988B1 (fr)
EP (1)	EP1107750B1 (fr)
AT (1)	ATE281832T1 (fr)
AU (1)	AU5024599A (fr)
BG (1)	BG105207A (fr)
CZ (1)	CZ292170B6 (fr)
DE (1)	DE69921832T2 (fr)
ES (1)	ES2229737T3 (fr)
HR (1)	HRP20010110B1 (fr)
HU (1)	HUP0104304A3 (fr)
NO (1)	NO20010507D0 (fr)
PL (1)	PL346363A1 (fr)
PT (1)	PT1107750E (fr)
RU (1)	RU2188640C1 (fr)
SK (1)	SK284711B6 (fr)
UA (1)	UA73281C2 (fr)
WO (1)	WO2000009097A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999051246A1 (fr)	1998-04-03	1999-10-14	Ajinomoto Co., Inc.	Agents antitumoraux
AU2005329764B2 (en) *	2005-03-28	2010-08-12	Dabur Pharma Ltd.	Stable pharmaceutical compositions of platinum (II) antitumour agents
KR101127159B1 (ko) *	2009-11-02	2012-03-20	한국생명공학연구원	식물병원성 그람음성 세균의 분비체계를 저해하는 카보프라틴 화합물을 유효성분으로 함유하는 식물병 방제제
CN112638363B (zh) *	2018-08-31	2025-01-24	太阳医药工业有限公司	卡铂的肠胃外剂型
US12427104B1 (en)	2025-04-01	2025-09-30	Ingenus Pharmaceuticals, Llc	Injectable carboplatin formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CS269719B1 (en) *	1986-12-29	1990-05-14	Kiss Frantisek	Platinum cytostatic
JPH01146826A (ja) *	1987-12-03	1989-06-08	Nippon Kayaku Co Ltd	白金化合物の凍結乾燥製剤
NL8901433A (nl) *	1989-06-06	1991-01-02	Pharmachemie Bv	Carboplatinpreparaat.
US5455270A (en) *	1993-08-11	1995-10-03	Bristol-Myers Squibb Co.	Stabilized solutions of platinum(II) antitumor agents
DE69427595T2 (de) *	1994-02-07	2002-04-25	Pliva Pharmaceutical Industry	Antitumormittel auf basis von carboplatin und herstellung desselben

1998
- 1998-08-14 CZ CZ19982588A patent/CZ292170B6/cs not_active IP Right Cessation
1999
- 1999-08-10 SK SK209-2001A patent/SK284711B6/sk not_active IP Right Cessation
- 1999-08-10 ES ES99934452T patent/ES2229737T3/es not_active Expired - Lifetime
- 1999-08-10 EP EP99934452A patent/EP1107750B1/fr not_active Expired - Lifetime
- 1999-08-10 PL PL99346363A patent/PL346363A1/xx not_active IP Right Cessation
- 1999-08-10 AU AU50245/99A patent/AU5024599A/en not_active Abandoned
- 1999-08-10 PT PT99934452T patent/PT1107750E/pt unknown
- 1999-08-10 HU HU0104304A patent/HUP0104304A3/hu unknown
- 1999-08-10 DE DE69921832T patent/DE69921832T2/de not_active Expired - Lifetime
- 1999-08-10 WO PCT/CZ1999/000028 patent/WO2000009097A2/fr not_active Ceased
- 1999-08-10 HR HR20010110A patent/HRP20010110B1/xx not_active IP Right Cessation
- 1999-08-10 US US09/762,458 patent/US6589988B1/en not_active Expired - Fee Related
- 1999-08-10 AT AT99934452T patent/ATE281832T1/de not_active IP Right Cessation
- 1999-08-10 RU RU2001104352/14A patent/RU2188640C1/ru not_active IP Right Cessation
- 1999-10-08 UA UA2001021022A patent/UA73281C2/uk unknown
2001
- 2001-01-30 NO NO20010507A patent/NO20010507D0/no not_active Application Discontinuation
- 2001-01-31 BG BG105207A patent/BG105207A/xx unknown

Also Published As

Publication number	Publication date
NO20010507L (no)	2001-01-30
EP1107750A2 (fr)	2001-06-20
CZ258898A3 (cs)	2000-02-16
RU2188640C1 (ru)	2002-09-10
DE69921832D1 (de)	2004-12-16
ATE281832T1 (de)	2004-11-15
US6589988B1 (en)	2003-07-08
NO20010507D0 (no)	2001-01-30
HUP0104304A3 (en)	2004-04-28
CZ292170B6 (cs)	2003-08-13
ES2229737T3 (es)	2005-04-16
PL346363A1 (en)	2002-02-11
SK284711B6 (sk)	2005-09-08
HRP20010110B1 (en)	2005-10-31
BG105207A (en)	2001-07-31
EP1107750B1 (fr)	2004-11-10
WO2000009097A3 (fr)	2000-05-18
HRP20010110A2 (en)	2002-02-28
SK2092001A3 (en)	2001-07-10
DE69921832T2 (de)	2005-11-03
HUP0104304A2 (hu)	2002-03-28
PT1107750E (pt)	2005-02-28
WO2000009097A2 (fr)	2000-02-24
AU5024599A (en)	2000-03-06

Publication	Publication Date	Title
RU2099350C1 (ru)	1997-12-20	Ассоциаты депротонированной гиалуроновой кислоты, способ их получения, фармацевтическая композиция, содержащая ассоциаты депротонированной гиалуроновой кислоты, и способ ее получения
AP957A (en)	2001-04-12	Novel stable liquid paracetamol compositions, and method for preparing same.
EP1225898B1 (fr)	2003-06-18	Compositions pharmaceutiques contenant un medicament antibiotique de fluoroquinolone et une gomme xanthan
KR101602000B1 (ko)	2016-03-17	안정한 트라넥삼산과 아스코르브산 함유 의약 조성물
Doverspike et al.	2019	Nitric oxide releasing two-part creams containing S-nitrosoglutathione and zinc oxide for potential topical antimicrobial applications
KR20110116194A (ko)	2011-10-25	헤스페리딘 함유 조성물
JPWO2008023807A1 (ja)	2010-01-14	安定化された医薬組成物
JPWO2001080858A1 (ja)	2003-07-22	安定化液状製剤
UA73281C2 (en)	2005-07-15	Antitumor pharmaceutical composition based on carboplatin
KR100440354B1 (ko)	2004-09-18	티아가빈염산염함유약학적조성물및그제조방법
JP4929352B2 (ja)	2012-05-09	注入可能なパラセタモール液剤
HU177557B (en)	1981-11-28	Process for preparing stable aequous sterile solution of cys-platinic/ii/-diamine-dichloride
JPS5914447B2 (ja)	1984-04-04	ｐＨおよび色安定化非経口投与用水性抗性物質組成物
EP0159777A1 (fr)	1985-10-30	4-Carbamoyl-imidazolium-5-stabilisé
SU1706372A3 (ru)	1992-01-15	Способ получени водных растворов винкристина или винбластина
KR0164601B1 (ko)	1999-01-15	비스-인돌알칼로이드를 함유하는 주사 용액및 그 제조방법
JPS6360008B2 (fr)	1988-11-22
RU2611839C1 (ru)	2017-03-01	Состав для производства йодосодержащих биологически активных добавок
CN101621992A (zh)	2010-01-06	具有醇糖-基的缓冲液的奥沙利铂药物组合物
US7812052B2 (en)	2010-10-12	Stable aqueous formulation of a platin derivative
HU181940B (en)	1983-11-28	Process for producing solutions of vincane derivatives for parentheral application
AU2009349348B2 (en)	2014-09-11	Liquid pharmaceutical form of alkylphosphocholine and method of preparing same
US4554164A (en)	1985-11-19	Parenteral formulation
KR960004018B1 (ko)	1996-03-25	L-글루타민과 수용성아줄렌 복합 항궤양용 제제의 안정화 방법
KR20030022740A (ko)	2003-03-17	디우리딘인산 함유 점안액